Xenoport, Inc.
3410 Central Expressway
Santa Clara,
CA 95051
United States - Map
Phone: 408-616-7200
Fax: 408-616-7210
Web Site: http://www.xenoport.com
| XenoPort, Inc., a biopharmaceutical company, focuses on developing internally discovered product candidates that utilize the bodys natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs. Its portfolio of product candidates includes XP13512, which is a transported prodrug of gabapentin, has been evaluated in a phase III clinical program for the treatment of restless legs syndrome, as well as completed a phase IIa clinical trial for the management of post-herpetic neuralgia; XP19986, a transported prodrug of R-baclofen for the treatment of gastroesophageal reflux disease and spasticity; and XP21279, a transported prodrug of levodopa, which is in phase I clinical trial for the treatment of Parkinsons disease. The company also develops XP21279, a transported prodrug of L-Dopa, for the treatment of Parkinsons disease; and XP21510, a transported prodrug of tranexamic acid, for the treatment of menorrhagia or heavy menstrual bleeding. XenoPort has strategic alliances with Astellas Pharma, Inc.; Glaxo Group Limited; and Xanodyne Pharmaceuticals, Inc. The company was founded in 1999 and is based in Santa Clara, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Ronald W. Barrett Ph.D., 53
Co-Founder, Chief Exec. Officer |
$
766.00K |
$
1.05M | Mr. William J. Rieflin , 48
Pres |
$
525.00K |
$
367.00K | Mr. William G. Harris , 50
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. |
N/A
| N/A | Mr. Vincent J. Angotti , 41
Chief Commercialization Officer and Sr. VP |
$
315.00K | N/A | Dr. David R. Savello Ph.D.,
Sr. VP of Devel. |
$
401.00K |
$
332.00K |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.06% Nasdaq 
Profile
